Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | BRAF |
| Variant | L525R |
| Impact List | missense |
| Protein Effect | gain of function - predicted |
| Gene Variant Descriptions | BRAF L525R lies within the protein kinase domain of the Braf protein (UniProt.org). L525R results in increased activation of Erk signaling in a dimer-dependent but RAS-independent manner (PMID: 31515458, PMID: 28972961), and therefore, is predicted to lead to a gain of Braf protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
BRAF mutant BRAF act mut BRAF L525R |
| Transcript | NM_004333.6 |
| gDNA | chr7:g.140777032A>C |
| cDNA | c.1574T>G |
| Protein | p.L525R |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_001354609.1 | chr7:g.140777032A>C | c.1574T>G | p.L525R | RefSeq | GRCh38/hg38 |
| XM_017012559.1 | chr7:g.140778054_140778055delTTinsAG | c.1573_1574delTTinsAG | p.L525R | RefSeq | GRCh38/hg38 |
| NM_001374244.1 | chr7:g.140778054_140778055delTTinsAG | c.1573_1574delTTinsAG | p.L525R | RefSeq | GRCh38/hg38 |
| XM_047420767.1 | chr7:g.140778054_140778055delTTinsAG | c.1573_1574delTTinsAG | p.L525R | RefSeq | GRCh38/hg38 |
| NM_004333.6 | chr7:g.140777032A>C | c.1574T>G | p.L525R | RefSeq | GRCh38/hg38 |
| NM_001378468.1 | chr7:g.140777032A>C | c.1574T>G | p.L525R | RefSeq | GRCh38/hg38 |
| NM_001374258.1 | chr7:g.140778054_140778055delTTinsAG | c.1573_1574delTTinsAG | p.L525R | RefSeq | GRCh38/hg38 |
| XM_047420769.1 | chr7:g.140777032A>C | c.1574T>G | p.L525R | RefSeq | GRCh38/hg38 |
| XM_017012558.1 | chr7:g.140778054_140778055delTTinsAG | c.1573_1574delTTinsAG | p.L525R | RefSeq | GRCh38/hg38 |
| XM_047420768.1 | chr7:g.140778054_140778055delTTinsAG | c.1573_1574delTTinsAG | p.L525R | RefSeq | GRCh38/hg38 |
| NM_001354609.2 | chr7:g.140777032A>C | c.1574T>G | p.L525R | RefSeq | GRCh38/hg38 |
| NM_004333.5 | chr7:g.140777032A>C | c.1574T>G | p.L525R | RefSeq | GRCh38/hg38 |
| XM_017012559.2 | chr7:g.140778054_140778055delTTinsAG | c.1573_1574delTTinsAG | p.L525R | RefSeq | GRCh38/hg38 |
| XM_047420766.1 | chr7:g.140776996_140776997delTTinsAG | c.1573_1574delTTinsAG | p.L525R | RefSeq | GRCh38/hg38 |
| NM_001378474.1 | chr7:g.140777032A>C | c.1574T>G | p.L525R | RefSeq | GRCh38/hg38 |
| NM_001378472.1 | chr7:g.140754198A>C | c.1574T>G | p.L525R | RefSeq | GRCh38/hg38 |
| NM_001378475.1 | chr7:g.140753297_140753298delTTinsAG | c.1573_1574delTTinsAG | p.L525R | RefSeq | GRCh38/hg38 |
| NM_001378473.1 | chr7:g.140754198A>C | c.1574T>G | p.L525R | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF L525R | colorectal cancer | not predictive | Cetuximab | Case Reports/Case Series | Actionable | In a clinical study, Erbitux (cetuximab) treatment as a third-line therapy resulted in stable disease with progression-free survival of 4 months in a patient with metastatic colorectal cancer harboring BRAF L525R (PMID: 31515458). | 31515458 |
| BRAF L525R | Advanced Solid Tumor | sensitive | Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Koselugo (selumetinib) inhibited viability of cells expressing BRAF L525R in culture (PMID: 36856908). | 36856908 |
| BRAF L525R | Advanced Solid Tumor | predicted - sensitive | Dactolisib + Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of Dactolisib (BEZ235) to treatment with Koselugo (selumetinib) resulted in increased inhibition of proliferation in Koselugo (selumetinib)-resistant cells expressing BRAF L525R compared to Dactolisib (BEZ235) alone (PMID: 36856908). | 36856908 |
| BRAF L525R | Advanced Solid Tumor | sensitive | Dactolisib | Preclinical - Cell culture | Actionable | In a preclinical study, Dactolisib (BEZ235) inhibited viability of cells expressing BRAF L525R in culture (PMID: 36856908). | 36856908 |